

CRISPRcon

Ideas Marketplace: Please visit whichever tables you like for informal dialogue with fellow CRISPRcon participants. You will have the opportunity to move to a different table about halfway through the session. *Note that all attendees who registered before September 24 were offered the chance to host a table when registering for CRISPRcon.*

Table	Discussion Topic & Host
1	Access and Innovation: Affordability of Gene Therapy, <i>Ben Steyer, University of Wisconsin-Madison School of Medicine and Public Health</i>
2	Applications of Gene Editing to Agricultural Pest Management, <i>Paul Mitchell, University of Wisconsin-Madison</i>
3	The Blurry Lines Between Cures, Treatments, and Enhancements, <i>Ryan Cross, Chemical & Engineering News</i>
4	Community and Institutional Partnerships: Moving from Race to Culture, <i>Craig Hassel, University of Minnesota, Cultural Wellness Center, Healing Roots Community</i>
5	Conservation Genetics to Save Ecosystems, <i>Francisco Pelegri, Genetics and Medical Genetics; Paul Robbins, Nelson Institute for Environmental Studies; Carol Barford, Center for Sustainability and the Global Environment</i>
6	Consumer Acceptance of Gene-Edited Animals and Row Crops, <i>Mike Paustian, Iowa Pork Producers Association; Megan Miller, Lynn Rohrscheib, Illinois Soybean Association</i>
7	CRISPR: Intellectual Property Landscape and Strategies, <i>Michael Stimson, Genus plc</i>
8	Digital Biology and Computational Thinking Using CRISPRs, <i>Ramesh Vaidyanathan, iGeneHub LLC</i>
9	Disability: Part of the Human Experience, <i>Jeremy Gundlach, Wisconsin Board for People with Developmental Disabilities</i>
10	Ethical Questions Around Germline Gene Editing, <i>Hille Haker, Loyola University Chicago</i>
11	Ethics and Obstacles to Using Gene Editing with Human Trials, <i>Brad Swail, Deletion Duplication Alliance</i>
12	FBI Weapons of Mass Destruction Program, <i>Special Agent Scott Mahloch, FBI Milwaukee WMD Program</i>
13	Gene Editing as a Rare Disease Therapeutic Platform: A New Paradigm, <i>Tom Foti, Aldevron</i>
14	Gene Editing in Food and Agriculture: What Do You Want to Know? <i>Sarah Gallo, BIO</i>
15	Gene Editing in Translational Medicine Institutes: How It Works, <i>Max Sellman, Aldevron</i>
16	Gene-Edited Foods and Global Commodity Impact, <i>Cassie J. Edgar, McKee, Voorhees & Sease, PLC</i>
17	Importance of Open Innovation for Technology Adoption, <i>Mat Muller, Corteva</i>
18	Indigenous Bio-Banking, <i>Joseph MV Yracheta, Native Bio-Data Consortium, Johns Hopkins Bloomberg School of Public Health</i>
19	Optimizing Edit Efficiency in Plants, <i>Andrew Bent, University of Wisconsin-Madison</i>
20	Specificity (Off-Target Effects) and Genome Editing Risks, <i>Mark Behlke, Integrated DNA Technologies, Inc.</i>
21	Tissue-Specific Delivery of Gene Editing Therapies: A Recent Breakthrough, <i>Krishanu Saha, Wisconsin Institute for Discovery</i>